Drug Trial Radar · NCT03058289
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
Last checked: Nov 19, 2026Latest source record: Feb 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
111
Actual
Start
Feb 9, 2017
Primary completion
Feb 22, 2023
Study completion Feb 22, 2023
Sponsor
- Lead sponsor
- Intensity Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC; Bristol-Myers Squibb
- First posted
- Feb 20, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluated the intratumoral administration of escalating doses of a novel, experimental drug, INT230-6. The study was conducted in patients with several types of refractory cancers including those at the surface of the skin (breast, squamous cell, head and neck) and tumors within the body such (pancreatic, colon, liver, lung, etc.). Sponsor also tested INT230-6 in combination with anti-PD-1 and anti-CTLA-4 antibodies.
Conditions
- Breast Cancer
- Head and Neck Cancer
- Squamous Cell Carcinoma
- Lymphoma
- Pancreatic Cancer
- Liver Cancer
- Colon Cancer
- Lung Cancer
- Bile Duct Cancer
- Chordoma of Sacrum
- Sarcoma
Interventions
INT230-6Drug
INT230-6 is clear sterile solution administered by injection directly into the tumor to be treated. The product contains a cell permeation agent with cisplatin and vinblastine sulfate at fixed concentrations.
anti-PD-1 antibodyBiological
The anti-PD-1 antibody will be added concomitantly with INT230-6 as noted in cohort DEC and DEC2
anti-CTLA-4 antibodyBiological
The anti-CTLA-4 antibody will be added concomitantly with INT230-6 as noted in cohort FEC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate and Severity of Treatment-emergent Adverse Events ≥ Grade 3 Attributed to Study Drug Using the NCI Common Terminology Criteria for Adverse Events (CTCAE v.4.03) (Scale 1 to 5)Time frame: Up to 5 years
Locations
8 sites in 2 countries. Site status is shown where the registry gives one.
USC Norris
Los Angeles, California
USC HOAG
Newport Beach, California
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland
UMASS Memorial Medical Center
Worcester, Massachusetts
Columbia University Medical Center
New York, New York
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Center for Oncology and Blood Disorders
Houston, Texas
Princess Margaret Cancer Center - University Health Network
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.